Introduction {#s1}
============

Disorders/differences of sex development (DSD) occur when there is a discordance between chromosomal, gonadal, and genital sex ([@B63]). DSD may be due to mutations in any of the genes involved in sex determination and development in general, as well as gonadal and/or genital development specifically ([@B63]).

*MAMLD1* (Xq28, OMIM 300120) is one of the recognized DSD-related genes ([@B27]; [@B2]). Variations in *MAMLD1* sequence have been described mainly in 46,XY DSD individuals, mostly associated with hypospadias ([@B27]; [@B43]; [@B16]; [@B42]; [@B55]; [@B9]; [@B35]; [@B24]), but also with other DSD phenotypes, including micropenis ([@B16]; [@B42]; [@B9]; [@B52]), and/or crypthorchidism ([@B27]; [@B43]; [@B42]; [@B9]), 46,XY with female external genitalia ([@B27]; [@B9]) and 46,XY with complete gonadal dysgenesis ([@B72]). Furthermore, one homozygous *MAMLD1* variant was also reported in a 46,XX patient with gonadal dysgenesis, primary amenorrhea, bilateral streak gonads and clitoromegaly ([@B8]).

However, the role of MAMLD1 in sex development is controversial for several reasons: a) some *MAMLD1* variants are present in the normal population ([@B27]; [@B16]; [@B29]; [@B41]); b) the same *MAMLD1* variant may be present in patients with different phenotypes ([@B9]); c) *MAMLD1* variants are not present in all DSD individuals of the same family ([@B27]); d) several *MAMLD1* mutations present wild-type activity in functional studies ([@B9]); and e) the *Mamld1*-knockout male mouse presents with normal genitalia and reproduction ([@B57]; [@B58]).

*MAMLD1* is expressed in human fetal and adult testis and in human ovaries ([@B27]; [@B62]; [@B9]), and seems to be involved in sex development in fetal life and in adult reproductive function. Yet its exact role is not clear. It is expressed in mice gonadal cells during start of androgen biosynthesis up to male external genitalia formation and is therefore thought to be involved in the expression of Leydig-cell genes ([@B57]), as well as supporting testosterone production in critical periods of male development ([@B28]; [@B60]). In contrast, *Mamld1*-KO mice present normal external genitalia (but small testes and reduced seminiferous tubule size and proliferating germ cells) and reproduce similarly to wild-type mice ([@B57]; [@B58]). These findings challenge the role of MAMLD1 in sex development.

In a previous study, we tested functional activity of nine *MAMLD1* variants detected in nine 46,XY DSD patients with broad phenotypes ([@B9]). None of the *MAMLD1* mutants, except truncated L210X, had diminished transcriptional activity on known target promoters *CYP17A1* and *HES3*. In addition, protein expression of *MAMLD1* variants was similar to wild-type, except for the truncated L210X. We therefore hypothesized that *MAMLD1* variants may not be sufficient to explain the phenotype in 46,XY DSD carriers, and that further genetic studies should be performed to search for additional hits explaining the broad variability.

In the past decade, High throughput sequencing (HTS) has changed the genetic approach in research and diagnostics. Whole-exome sequencing (WES) has led to the discovery of many new genes and has given insight into complex traits. Oligogenic inheritance is currently discovered for several disorders by HTS. In the field of sex development, digenic inheritance has recently been suggested in a 46,XY DSD patient with gonadal dysgenesis (*NR5A1* and *MAP3K1* variants) ([@B53]); in a family with 46,XY DSD males (*NR5A1* variants) and 46,XX POF females (*NR5A1* and *TBX2*) ([@B83]); as well as in a DSD patient with ambiguous genitalia, micropenis, and inguinal testes (*SEMA3A* and *AKR1C4*) ([@B25]). Similarly, we found oligogenic origin of disease in heterozygous *NR5A1* 46,XY DSD patients by performing WES ([@B10]). In addition, in patients with hypospadias, an oligogenic origin was suggested by two other NGS studies ([@B46]; [@B24]).

Therefore, in this study, we performed WES in seven 46,XY patients with DSD ([@B9]) and one 46,XX patient with ovarian insufficiency, who all carried *MAMLD1* variants. WES data were filtered by common tools and a disease-tailored algorithm including *MAMLD1*-related and DSD-related known and candidate genes. Additional hits in likely disease-causing genes were detected in all eight *MAMLD1* carriers. Our results suggest that oligogenic origin of disease may contribute towards the broad phenotypes of human *MAMLD1*.

Patients and Methods {#s2}
====================

Patients {#s2_1}
--------

The study was approved by the Ethics Committee of Hospital Universitari Vall d\'Hebron (Barcelona, Spain) (CEIC: PR(IR)23/2016). Written informed consent was obtained from the patients for the publication of their cases. Eight DSD patients (seven 46,XY and one 46,XX) each carrying one *MAMLD1* variant were analyzed using WES. Clinical and genetic characteristics of 46,XY patients were previously reported in detail in [@B9] and are summarized in [**Table 1**](#T1){ref-type="table"} together with the 46,XX patient.

###### 

Clinical, biochemical and genetic characteristics of the studied *MAMLD1* patients.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Karyotype\     Phenotype and origin                                                                               Gonadal function (age)                               Adrenal function (age)   *MAMLD1* variant                              Variants after filtering by gene list (A)   Candidate variants (B)   Candidate genes (C)
            assigned sex                                                                                                                                                                                                                                                                                                       
  --------- -------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------ --------------------------------------------- ------------------------------------------- ------------------------ ---------------------
  1\        46,XY\         Penoscrotal hypospadias.\                                                                          Normal hCG test.                                     Normal Synacthen test.   p.V505A NM_005491:c.1514T\>C\                 547                                         9                        7
  (7)       Female         Small penis.\                                                                                                                                                                                                                                                                                       
                           Unilateral cryptorchidia.\                                                                                                                                                                                                                                                                          
                           Histology: normal for age (2y).\                                                                                                                                                                                                                                                                    
                           Venezuelan origin.                                                                                                                                                                                                                                                                                  

  2\        46,XY\         Penoscrotal hypospadias.\                                                                          Normal baseline T (3m).\                             Normal baseline\         p.A503E NM_005491:c.1508C\>A                  492                                         1                        1
  (6)       Male           Small penis.\                                                                                      Normal hCG test (9m).                                (3d).                                                                                                                                       
                           Testes: 2 ml.\                                                                                                                                                                                                                                                                                      
                           Spanish origin.                                                                                                                                                                                                                                                                                     

  3\        46,XY\         Penoscrotal hypospadias.\                                                                          Normal baseline (12m).\                              NA                       p.S730S NM_005491:c.2190G\>A                  570                                         2                        2
  (9)       Female         Small penis.\                                                                                      No hCG test.                                                                                                                                                                                     
                           Histology: normal for age (nests of normal Leydig cells; normal fertility index (1y)\                                                                                                                                                                                                               
                           Müllerian ducts.\                                                                                                                                                                                                                                                                                   
                           Spanish origin                                                                                                                                                                                                                                                                                      

  4\        46,XY\         Female genitalia.\                                                                                 Normal hCG test (2y).                                Normal baseline\         p.H347Q NM_005491:c.1041C\>A\                 633                                         4                        4
  (3)       Female         Gonads in labia.\                                                                                                                                       (2y).                    *rs62641609*                                                                                                       
                           Spanish origin.                                                                                                                                                                                                                                                                                     

  5\        46,XY\         Penoscrotal hypospadias.\                                                                          Normal hCG test.\                                    Normal baseline\         p.H347Q NM_005491:c.1041C\>A\                 929                                         6                        6
  (4)       Male           Testes 2 ml.\                                                                                      Normal AMH (2.5y).                                   (2.5y).                  *rs62641609*                                                                                                       
                           Spanish origin.                                                                                                                                                                                                                                                                                     

  6\        46,XY\         Penoscrotal hypospadias.\                                                                          Normal prepubertal baseline T (15 m).\               Normal baseline\         p.L724V NM_005491:c.2170C\>G                  710                                         16                       16
  (8)       Male           Small penis.\                                                                                      Normal AMH.                                          (15 m).                                                                                                                                     
                           Testes 1 ml.\                                                                                                                                                                                                                                                                                       
                           Esophageal atresia.\                                                                                                                                                                                                                                                                                
                           Right aortic arch.\                                                                                                                                                                                                                                                                                 
                           North African origin.                                                                                                                                                                                                                                                                               

  7\        46,XY\         Hypospadias.\                                                                                      Normal baseline\                                     Normal baseline\         *p.Q501Q502* NM_005491:c.1503_1504dupCAGCAG   429                                         5                        5
  (5)       Male           Short penis.\                                                                                      T and gonadotropins (70y).\                          (70y).                                                                                                                                      
                           Testes 8 ml.\                                                                                      Fathered a boy.                                                                                                                                                                                  
                           Delayed puberty.\                                                                                                                                                                                                                                                                                   
                           Gynaecomastia.\                                                                                                                                                                                                                                                                                     
                           Fathered a boy.\                                                                                                                                                                                                                                                                                    
                           Swiss origin.                                                                                                                                                                                                                                                                                       

  8         46,XX\         Female external genitalia.\                                                                        High gonadotropins and low/normal estradiol (27y).   Normal (27y).            NM_005491:c.\*126C\>MIT                       574                                         14                       13
            Female         Small ovaries and uterus, with fallopian tubes. Primary amenorrhea (15y).\                                                                                                                                                                                                                          
                           Histology: large amount of primordial follicles (no evidence of maturation), atresic follicles.\                                                                                                                                                                                                    
                           Delayed growth.\                                                                                                                                                                                                                                                                                    
                           Spanish origin.                                                                                                                                                                                                                                                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All patients presented one hemizygous/heterozygous variant in MAMLD1. In parentheses: patients in [@B9]; NA, not analyzed; d, day(s); m, month(s); y, year(s). (A) Filtered by DSD-related and MAMLD1-related gene list. (B) Number of candidate variants per patient: related to sex development, DSD phenotypes, and/or in MAMLD1-related genes, and with MAF ≤ 0.01. (C) Number of candidate genes per patient: genes containing at least one candidate variant per patient.

DNA Extraction, WES and Bioinformatic Analysis {#s2_2}
----------------------------------------------

DNA was extracted from blood leukocytes using QiaCube (Qiagen, Hilden, Germany) or manually using a DNA isolation kit (Qiagen). WES was performed by CNAG (Centre Nacional d'Anàlisi Genòmica, Barcelona, Spain). Libraries were prepared with a SureSelect Human All Exon V5 capture kit (Agilent, Santa Clara, CA, USA) and sequenced with a HiSeq™ 2000 sequencing system (v3, 2x100, Illumina, San Diego, CA, USA). Putative candidate variants were confirmed by Sanger sequencing.

The genomic datasets were annotated (alignment with human genome hg19/grch37) and filtered with the functional annotation of genetic variants from HTS data (ANNOVAR; <http://annovar.openbioinformatics.org/>) ([@B79]), visualized and explored in Integrative Genomics Viewer (IGV, Broad Institute, Cambridge, MA, USA; <https://www.broadinstitute.org/igv/> ([@B71]). Frequencies of variants of relevant candidate genes were obtained from the Genome Aggregation Database (gnomAD; <http://gnomad.broadinstitute.org/about>) ([@B49]) and the Collaborative Spanish Variant Server (CSVS; CIBERER BIER, Valencia, Spain; <http://csvs.babelomics.org/>; August 2018) ([@B22]). gnomAD includes gene variants from exome and genome sequencing data: 123,136 exomes and 15,496 genomes from unrelated individuals (from population and disease-specific studies). CSVS database includes (among others) exomes from a population of 267 healthy unrelated subjects.

WES data were filtered by a disease-tailored list of *MAMLD1*-related and DSD-related known and candidate genes (n = 606) similar to the algorithm previously set up for [@B10]. We generated a project-specific filter for DSD-related and *MAMLD1*-related genes by searching in published literature and databases. DSD-related genes are part of our DSD-gene database and tools ([@B10]), which have been currently updated. The DSD-related gene list included genes with reported (potentially) deleterious variants in patients with 46,XY and 46,XX DSD, genes with reported (potentially) disease-causing variants in syndromic patients with involvement of sex development, those "related" to DSD conditions in KO/mutant animal models (mice and rats), and also overexpressed, upregulated or downregulated genes in rodent embryonic gonadal cells ([@B10]). For the search for functional human partners of MAMLD1 and for possible interactions within interesting genes, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, <http://string-db.org/>) ([@B39]) and the Biological General Repository for Interaction Datasets (BioGRID, thebiogrid.org) ([@B75]) were used.

We used 30 pathogenic predictors to predict possible impact of amino acid substitutions on the structure, function and evolutionary conservation of corresponding human proteins and to predict impact on splicing. These *in-silico* predictors were accessed through ANNOVAR ([@B79]) annotation and run through Alamut Visual 2.11 (<https://www.interactive-biosoftware.com/es/alamut-visual/>). Functional exonic predictors were CADD (Combined Annotation Dependent Depletion of single-nucleotide and insertion/deletion variants, <http://cadd.gs.washington.edu/>) ([@B45]), SIFT (Scale-invariant feature transform; <http://sift.jcvi.org/>), PolyPhen-2 (Polymorphism Phenotyping v2: HumDiv, HumVar; <http://genetics.bwh.harvard.edu/pph2/index.shtml>), Provean (<http://provean.jcvi.org>), MutationAssessor (<http://mutationassessor.org/r3/>), Mutation Taster (<http://www.mutationtaster.org/>), LRT, FATHEMM, Fathmm-MKL, PROVEAN, VEST3 (Variant Effect Scoring Tool), MetaSVM, MetaLR, MCAP, DANN and fitCons. Exonic predictors on evolutionary conservation were: GERP++, phyloP (vertebrate and mammalians), phastCons (vertebrate and mammalians) and SiPhy. Splicing predictors were: splicing predictors from dbscSNV ADA and RF and SPIDEX splicing predictor (DPSI), and those splicing predictors from Alamut Visual software were: SSF, MaxEnt, NNSPLICE, GeneSplicer and Ex-Skip.

The following bioinformatics software tools were used for the interpretation and classification of variants: InterVar (<http://wintervar.wglab.org/>, clinical interpretation of genetic variants by the ACMG/AMP 2015 guideline), VarSome (The Human Genomics Search Engine; <https://varsome.com/>), ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and Alamut Visual 2.11 (<https://www.interactive-biosoftware.com/es/alamut-visual>/). We searched for reported (potentially) disease-causing variants with the Human Gene Mutation Database (HGMD^®^ Professional 2018.2, <http://www.biobase-international.com/product/hgmd>; Biobase) and dbSNP (<http://www.ncbi.nlm.nih.gov/snp/>). We used STRING for the search for interactions within genes carriers of interesting variants (DSD-related and/or *MAMLD1*-related). Data from STRING are extracted from known interactions (curated databases, experimentally determined interactions), predicted interactions (gene neighborhood, gene fusions, gene co-occurrence) and other inferred evidences such as text mining, co-expression and protein homology. We used Pubmed (<https://www.ncbi.nlm.nih.gov/pubmed/>) and OMIM (<https://www.omim.org>) to build our DSD gene list and for further data analysis. The datasets generated for this study are publicy available in dbSNP ([@B74]): <https://www.ncbi.nlm.nih.gov/projects/SNP/snp_viewBatch.cgi?sbid=1063030>.

Variant Analysis Per Patient {#s2_3}
----------------------------

After annotation, variant analysis was performed by the following steps. A) Each patient's WES data were first filtered by our *MAMLD1*- and DSD-related known and candidate genes. B) We kept variants with MAF (minor allele frequency) ≤0.015 or not detected in gnomAD, and variants with the following predicted type, consequences and locations: splicing (intronic or exonic), exonic, intergenic, regulatory. C) We confirmed the correct annotation and location of variants by checking their alignment data in IGV (alignment with human genome hg19/grch37) (data not shown). D) We excluded variants that were considered non-relevant for our study: E.g. 1) variants found in more than two patients, 2) variants in repeat regions, 3) variants in genes or gene regions with high variability, 4) variants with low coverage and/or low quality, 5) variants with non-similar allelic depths. E) We revised variants with the annotated pathogenic predictors: functional exonic, evolutionary-conservation and splicing predictors (ANNOVAR and Alamut Visual software), as previously described. F) We run InterVar and VarSome to classify the variants, searched for reported (potentially) human disease-causing variants with the HGMD, and revised evidences of relationship with DSD, sex development and clinical phenotype of each patient with literature and database search. G) We used STRING to find out interactions among genes carriers of interesting variants (DSD-related and/or *MAMLD1*-related) ([**Figures 1**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"}). H) We checked MAF in a healthy cohort of Spanish population (CSVS: 267 unrelated healthy controls). I) We rejected variants with MAF ≥ 0.01 (gnomAD, CVSV, August 2018), thus less plausible to be a DSD-causing variant. Importantly, synonymous variants were not rejected because it has been shown that they may affect splicing.

![Interaction network of DSD- and *MAMLD1*-related genes identified in DSD individuals harboring genetic variants in *MAMLD1*. The scheme depicts an overview of detected genes and their interrelationship. For the search for functional human partners, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, <http://string-db.org/>) was used. Nodes represent proteins. Filled nodes show proteins with known or predicted 3D structure. Empty nodes depict proteins with unknown 3D structure. Candidate genes are underlined. Known interactions correspond to curated databases (turquoise lines) and experimentally determined interactions (pink lines). Predicted interactions correspond to gene neighborhood (green lines), gene fusions (red lines) and gene co-occurrence (blue lines). Other interactions correspond to text mining (yellow lines), co-expression (black lines) and protein homology (violet lines).](fgene-10-00746-g001){#f1}

![Interaction networks of DSD- and *MAMLD1*-related genes identified per single *MAMLD1* individual. **(A)** to **(F)** correspond to the interaction networks per patient. For the search for functional human partner, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, <http://string-db.org/>) was used. Nodes represent proteins. Filled nodes show proteins with known or predicted 3D structure. Empty nodes depict proteins with unknown 3D structure. Candidate genes are underlined. Known interactions correspond to curated databases (turquoise lines) and experimentally determined interactions (pink lines). Predicted interactions correspond to gene neighborhood (green lines), gene fusions (red lines) and gene co-occurrence (blue lines). Other interactions correspond to text mining (yellow lines), co-expression (black lines) and protein homology (violet lines). Genes with no interactions are on the right side of each network.](fgene-10-00746-g002){#f2}

Results {#s3}
=======

WES performed in eight unrelated subjects (seven 46,XY and one 46,XX) harboring hemizygous/heterozygous *MAMDL1* variants revealed several candidate gene variants that potentially contribute to each patient's phenotype. A detailed summary of patients' characteristics and number of variants and genes is shown in [**Table 1**](#T1){ref-type="table"}. A list of identified candidate variants and corresponding information from literature is given in [**Table 2**](#T2){ref-type="table"}.

###### 

Identified genes and variants per patient after specific filtering.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   *Gene*       Chromosome: Coordinates   Type/consequence         HGVSc,HGVSp                                  dbSNP ID       gnomAD: MAF   CSVS: MAF   Predictors   Interpretation/classification (6)   Evidence                                                                                                                                                               
  --------- ------------ ------------------------- ------------------------ -------------------------------------------- -------------- ------------- ----------- ------------ ----------------------------------- ---------- ---- ---- ------------------- ------------------------------ ------------------- --------------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1         *CYP1A1*     15:75013544               snv/missense             NM_000499.5:c.1162C\>G:p.(His388Asp)         --             ND            ND          24.9         13                                  6          0    5    VUS                 ND                             --                  VUS: PM2, PP3                           No                                 Association to hypospadias (ᴔ[@B78])

  1         *EVC*        4:5798754                 snv/missense             NM_153717.2:c.1892C\>T:p.(Thr631Met)         rs139481521    0.0003        ND          23.5         5                                   3          0    3    VUS                 VUS                            --                  VUS: BP4                                No                                 Syndromic (Ellis--van Creveld syndrome) micropenis ([@B20]; [@B34]), gonadal development? ([@B5]; [@B38])

  1         *EVC*        4:5785368                 snv/synonymous           NM_153717.2:c.1653G\>A:p.(Pro551=)           rs151293705    0.0003        ND          2.382        NA                                  NA         1    3    Likely benign       other                          VUS                 VUS: BP7                                No                                 Syndromic (Ellis--van Creveld syndrome) micropenis ([@B20]; [@B34]), gonadal development? ([@B5]; [@B38])

  1         *GRID1*      10:87966142               snv/missense             NM_017551.2:c.499A\>G:p.(Met167Val)          rs956188880    0.00004       ND          10.04        1                                   5          0    NA   VUS                 ND                             --                  VUS: BP4                                No                                 Candidate to hypospadias ([@B78])

  1         *NOTCH1*     9:139399213               snv/synonymous           NM_017617.5:c.4930C\>T:p.(Leu1644=)          rs568700183    0.0003        ND          0.018        NA                                  NA         0    4    Likely benign       Likely benign\|Likely benign   Likely benign       Likely benign: BP6, BP7                 No                                 Related to SHH and FGF10 ([@B32])

  1         *RET*        10:43609955               snv/missense             NM_020975.5:c.1907C\>T:p.(Thr636Met)         rs1035958105   0.00001       0           23.0         6                                   6          0    NA   VUS                 VUS                            VUS                 Likely pathogenic: PM1, PM2, PP2, PP3   DM; thyroid carcinoma              Syndromic (CAKUT syndrome) cryptorchidism (ᴔ[@B14]), gonadal development? ([@B38]; [@B50])

  1         *RIPK4*      21:43161468               snv/missense             NM_020639.2:c.1885G\>A:p.(Asp629Asn)         rs199669994    0.00004       ND          7.899        4                                   4          NA   NA   VUS                 ND                             --                  VUS: PM2 BP1                            No                                 Syndromic (Popliteal pterygium syndrome) genital hypoplasia ([@B56]), micropenis, hypoplastic scrotum, inguinal hernia ([@B40]), gonadal development? ([@B5]; [@B38])

  1         *RIPK4*      21:43176830               snv/missense             NM_020639.2:c.329C\>T:p.(Ser110Leu)          rs200823657    0.00005       ND          22.7         3                                   5          0    NA   VUS                 NDw                            --                  VUS: PM2 BP1                            No                                 Syndromic (Popliteal pterygium syndrome) genital hypoplasia ([@B56]), micropenis, hypoplastic scrotum, inguinal hernia ([@B40]), gonadal development? ([@B5]; [@B38])

  1         *ZBTB16*     11:114027160              snv/intronic             NM_006006.5:c.1366+4G\>C                     --             ND            ND          13.81        NA                                  NA         1    4    ND                  ND                             --                  VUS: PM2 BP1                            No                                 Syndromic (deletion 11q23) cryptorchidism and micropenis ([@B26])

  2         *RECQL4*     8:145738828               snv/missense             NM_004260.3:c.2237C\>T:(p.Ala746Val)         rs201883228    0.0002        ND          26.8         6                                   5          NA   NA   VUS                 VUS                            VUs                 VUS: BP1                                No                                 Syndromic (Rothmund--Thomson syndrome) hypospadias, bilateral inguinal hernia ([@B44])

  3         *GLI2*       2:121747688               snv/missense             NM_005270.4:c.4198G\>T:p.(Gly1400Cys)        rs143914758    0.0001        ND          23.4         7                                   2          NA   NA   Likely benign       ND                             VUS                 VUS: -                                  No                                 Increased risk of hypospadias ([@B11]), male gonadal development ([@B38]), masculinization of male external genitalia ([@B69])

  3         *RECQL4*     8:145737701               snv,missense             NM_004260.3:c.3062G\>A:p.(Arg1021Gln)        rs34666647     0.004                     2.375        2                                   0          0    4    Likely benign       other\|Benign                  Benign              Likely benign: PM2, PM5, BP1, BP4       Cancer                             Syndromic (Rothmund--Thomson Syndrome) hypospadias, bilateral inguinal hernia ([@B44])

  4         *CDH23*      10:73559034               snv/nonsense             NM_022124.5:c.7221C\>A:p.(Tyr2407\*)         rs779038178    ND            0.002       35           5                                   6          1    3    Likely pathogenic   ND                             --                  Pathogenic: PVS1, PM2, PP3              No                                 Gonadal development? ([@B38]; [@B50])

  4         *COL9A3*     20:61448956               snv/missense             NM_001853.4:c.116C\>G:(p.(Pro39Arg)          rs1028982816   0.00001       ND          22.7         12                                  5          0    NA   VUS                 ND                             --                  VUS: PP3                                No                                 Male gonadal development ([@B61]; [@B5]; [@B38])

  4         *MAML1*      5:179193385               snv/synonymous           NM_014757.4:c.1374C\>T:p.(Asp458=)           rs61748799     0.003         0.004       0.089        NA                                  NA         0    1    Likely benign       ND                             --                  VUS: BP7                                No                                 No (MAMLD1-related)

  4         *NOTCH1*     9:139401803               snv/synonymous           NM_017617.5:c.3597C\>T:p.(Leu1199=)          rs150666307    0.00009       ND          11.70        NA                                  NA         0    3    Likely benign       Likely benign                  Likely benign       Likely benign: BP6, BP7                 No                                 Related to SHH and FGF10 ([@B32])

  5         *BNC2*       9:16436324                snv/missense             NM_017637.5:c.1868C\>A:p.(Pro623His)         rs114596065    0.0022        0.002       5.290        8                                   6          NA   NA   Benign              Benign                         Benign              VUS: BP6                                No                                 Hypospadias ([@B6]; [@B78]; [@B2]; [@B46]), gonadal development? ([@B38])

  5         *FGF10*      5:44388817                snv/upstream/missense    NG_011446.1:c.-33G\>A                        rs17233910     0.005         0.002       19.99        NA                                  NA         NA   NA   ND                  ND                             --                  VUS: -                                  No                                 Increased risk hypospadias in human ([@B78]; [@B11]; [@B76]); development of the glans penis ([@B69])

  5         *HSD3B2*     1:119964831               snv/missense             NM_000198.3:c.707T\>C:p.(Leu236Ser)          rs35887327     0.003788      ND          8.277        3                                   3          NA   NA   Likely benign       VUS                            VUS                 Likely Pathogenic: PS1, PP2, PP5, BP4   DM?; HSD3B2 deficiency             Hypospadias ([@B18]; [@B46]; [@B24]), sex development ([@B1]; [@B2]), hormone synthesis (ᴔ[@B54])

  5         *IRX5*       16:54967040               snv/missense             NM_005853.5:c.707C\>T:p.(Pro236Leu)          rs115549200    0.0088        ND          11.97        3                                   4          NA   NA   Benign              ND                             --                  VUS: BP4                                No                                 Association to hypospadias ([@B30]; [@B32]), female gonadal development? ([@B61])

  5         *MAML2*      11:95826473               snv/missense             NM_032427.3:c.722G\>A:p.(Arg241Gln)          rs111958464    0.005         ND          32           6                                   6          0    NA   VUS                 ND                             --                  VUs: -                                  No                                 No (MAMLD1-related)

  5         *NOTCH2*     1:120469147               snv/nonsynonymous        NM_024408.3:c.3980A\>G:p.(Asp1327Gly)        rs61752484     0.0037        0.004       20.4         6                                   6          0    NA   Likely benign       Benign                         Benign              VUS: BP6                                DM?; cardiopathy                   Primary ovarian failure ([@B64]); male gonadal development? ([@B38])

  6         *ATF3*       1:212788544               snv/missense             NM_001674.3:c.181G\>T:p.(Ala61Ser)           --             ND            ND          7.826        3                                   5          1    NA   Benign              ND                             --                  VUS: PM2, BP4                           No                                 Hypospadias ([@B4]; [@B78]), female gonadal development? ([@B38])

  6         *BNC2*       9:16436324                snv/missense             NM_017637.5:c.1868C\>A:p.(Pro623His)         rs114596065    0.0022        0.002       5.290        8                                   6          NA   NA   Benign              Benign                         Benign              VUS: BP6                                No                                 Hypospadias ([@B6]; [@B78]; [@B2]; [@B46]), gonadal development? ([@B38])

  6         *CYP1A1*     15:75012979               snv/missense             NM_001319216.2:c.1303C\> A:p.(Arg435Ser)     rs41279188     0.0047        ND          33           11                                  5          NA   NA   VUS                 ND                             Benign              VUS: PP3, BP6                           No                                 Association to hypospadias ([@B78])

  6         *EYA1*       8:72211882                snv/synonymous           NM_000503.5:c.630T\>C:p.(Ser210=)            rs373102227    0.00008       ND          10.56        NA                                  NA         1    4    Likely benign       VUS                            VUS                 VUS: PP3, BP7                           No                                 Associated to hypospadias ([@B32]; [@B33]), male gonadal development? ([@B38])

  6         *FLNA*       X:153596078               snv/synonymous           NM_001456.3:c.651C\>T:p.(Asp217=)            rs34644500     0.0002        ND          5.473        NA                                  NA         1    3    Likely benign       Likely benign                  Likely benign       Likely benign: BP4, BP6, BP7            No                                 Hypospadias, cryptorchidism, diminished androgen receptor ([@B12]), female gonadal development? ([@B38])

  6         *FRAS1*      4:79334181                snv/missense             NM_025074.6:c.4367T\>C:p.(Ile1456Thr)        rs560902495    0.00003       ND          24.6         12                                  5          NA   NA   VUS                 ND                             --                  VUS: PM2, PP3, BP1                      No                                 Syndromic (Fraser syndrome) abnormal genitourinary system ([@B67]; [@B47]); female gonadal development? ([@B38])

  6         *GLI3*       7:42066017                snv/intronic             NM_000168.5:c.1029-6G\>A                     rs748670269    0.00002       ND          0.004        NA                                  NA         0    3    NA                  ND                             --                  VUS: BP4                                No                                 Increased risk of hypospadias ([@B11]), early genital primordia ([@B68]), female gonadal development? ([@B38])

  6         *HOXA13*     7:27239079                snv/missense             NM_000522.4:c.618C\>G:p.(Phe206Leu)          rs774388075    0.00002       ND          22.3         5                                   5          NA   NA   VUS                 ND                             --                  VUS: -                                  No                                 Associated to hypospadias ([@B3]; [@B78]; syndromic, Hand-foot-genital)/Guttmacher syndrome) hypospadias ([@B36]), small penis ([@B31]), genital tubercle development ([@B32])

  6         *IRX5*       16:54965347               deletion/inframe         NM_005853.5:c.240_242delCTC:p.(Ser81del)     rs1057518726   ND            ND          --           NA                                  NA         NA   NA   NA                  VUS                            VUS                 VUS: PM4: nonframeshift deletion        No                                 Association to hypospadias ([@B30]; [@B32]), female gonadal development? ([@B61])

  6         *IRX6*       16:55362842               snv/missense             NM_024335.2:c.952T\>A:p.(Phe318Ile)          rs61743419     0.0014        ND          5.599        3                                   4          0    NA   VUS                 ND                             --                  VUS: -                                  No entry for this gene             Associated to hypospadias ([@B32])

  6         *MAML1*      5:179193168               snv/missense             NM_014757.4:c.1157G\>T:p.(Gly386Val)         rs777367230    0.0001        0.003       22.9         9                                   5          0    NA   VUS                 ND                             --                  VUS: -                                  No                                 No (MAMLD1-related)

  6         *MAML3*      4:140811687\              snv/synonymous           NM_018717.5:c.903C\>T:p.(Asp301=)            rs76066862     0.0015        0.002       2.445        NA                                  NA         NA   2    Likely benign       ND                             --                  VUS: -                                  No                                 Female gonadal development? ([@B38])
                         NOT CONFIRMED                                                                                                                                                                                                                                                                                                                                                    

  6         *NRP1*       10:33469272               snv/missense             NM_003873.5:c.2504G\>A:p.(Gly835Asp)         --             ND            ND          5.556        6                                   4          NA   NA   VUS                 ND                             --                  VUS: PM2                                No                                 DSD ([@B2]), gonadal development? ([@B38])

  6         *PROP1*      5:177421299               deletion/frameshift      NM_006261.4:c.150delA:p.(Arg53Aspfs\*112)    rs587776683    ND            ND          --           NA                                  NA         NA   NA   NA                  Pathogenic                     Likely pathogenic   VUS: PVS1, PP5                          DM; pituitary hormone deficiency   No, hypogonadotropic hipogonadism ([@B70]; [@B70]; [@B1]; [@B2]; [@B24])

  6         *PTPN11*     12:112856827              snv/upstream             NM_002834.4:c.-89G\>A                        --             ND            ND          16.23        NA                                  NA         NA   NA   NA                  ND                             --                  VUS: PM2, PP3                           No                                 Syndromic (Noonan syndrome) cryptorchidism ([@B77])

  6         *WDR11*      10:122668121              snv/missense             NM_018117.11:c.3571G\>A:p.(Gly1191Ser)       rs149486212    0.0001        0.004       34           14                                  5          NA   NA   VUS                 ND                             --                  VUS : PP2, PP3                          No                                 Hypospadias (ᴔ[@B24], [@B25]), small testes (ᴔ[@B25])

  7         *EVC*        4:5800455                 snv/missense             NM_153717.2:c.2240C\>T:p.(Ala747Val)         rs151091776    0.0002        ND          18.37        5                                   4          0    NA   VUS                 ND                             --                  VUS: BP4                                No                                 Syndromic (Ellis--van Creveld syndrome) hypospadias ([@B20]) and micropenis ([@B34]), gonadal development? ([@B5]; [@B38])

  7         *MAML3*      4:140811709               snv/missense             NM_018717.5:c.881A\>G:p.(Asn294Ser)          rs115966590    0.0028        ND          13.26        7                                   6          NA   NA   VUS                 ND                             --                  VUS: -                                  No                                 Female gonadal development? ([@B38])

  7         *NOTCH2*     1:120458982               snv/missense             NM_024408.3:c.6363G\>C:p.(Lys2121Asn)        rs144047610    0.0004        0.002       23.4         9                                   5          NA   NA   VUS                 VUS                            VUS                 VUS: -                                  DM?, Bicuspid aortic valve         Primary ovarian failure ([@B64]); male gonadal development? ([@B38])

  7         *PPARGC1B*   5:149219653               snv/missense             NM_133263.3:c.2668G\>A:p.(Ala890Thr)         rs150637009    0.0056        ND          19.13        5                                   5          0    NA   VUS                 ND                             --                  VUS: BP4                                No                                 Candidate to hypospadias ([@B78])

  7         *WDR11*      10:122637900              snv/missense             NM_018117.11:c.1592C\>G:p.(Ser531Cys)        rs775506715    0.00004       ND          24.1         14                                  6          1    NA   VUS                 ND                             --                  VUS: PP2, PP3                           No                                 Hypospadias (ᴔ[@B24], [@B25]), small testes (ᴔ[@B25])

  8         *CUL4B*      X:119708447               snv/missense             NM_003588.3:c.26G\>A:p.(Gly9Glu)             rs149016283    0.0002        ND          18.73        1                                   NA         1    NA   Likely benign       Likely benign                  Likely benign       Likely benign: BP4, BP6                 No                                 Abnormal genitourinary system ([@B67])

  8         *DAPK1*      9:90321476                snv/missense             NM_004938.3:c.3490G\>A:p.(Asp1164Asn)        rs937952689    0.00007       ND          24.3         8                                   5          NA   NA   VUS                 ND                             --                  VUS: -                                  No                                 Female gonadal development? ([@B38])

  8         *EMX2*       10:119305133              snv/intronic             NM_004098.3:c.407-10C \>T                    --             0.000004      ND          9.098        NA                                  NA         1    4    ND                  ND                             --                  VUS: BP4                                No                                 46,XX DSD ([@B51]), sex determination ([@B7]; [@B37]; [@B23]), (female) gonadal development ([@B69]; [@B38]; [@B32]), ([@B38]); 46,XY DSD ([@B65])

  8         *FREM2*      13:39454885               insertion/frameshift     NM_207361.5:c.9472dupC:p.(Gln3160Thrfs\*6)   --             ND            ND          --           NA                                  NA         NA   NA   ND                  ND                             --                  Likely pathogenic: PVS1, PM2            No                                 Syndromic (Fraser syndrome) abnormal genitalia ([@B21]), female gonadal development ([@B38])

  8         *IGFBP2*     2:217526593               snv/missense             NM_000597.3:c.685C\>A:p.(Gln229Lys)          --             ND            ND          23.7         8                                   6          0    NA   VUS                 ND                             --                  VUS: PM2, PP3                           No entry for this gene             Candidate gene in ovary development ([@B17]), female gonadal development? ([@B38]; [@B59]).

  8         *MAML2*      11:95826575               snv/missense             NM_032427.3:c.620G\>A:p.(Arg207His)          rs191391876    0.0002        ND          24.4         9                                   5          0    NA   VUS                 ND                             --                  VUS: -                                  No                                 No (MAMLD1-related)

  8         *MAML3*      4:140811709               snv/missense             NM_018717.5:c.881A\>G:p.(Asn294Ser)          rs115966590    0.0028        0.004       13.26        7                                   6          NA   NA   VUS                 ND                             --                  VUS: -                                  No                                 Female gonadal development? ([@B38])

  8         *MYO7A*      11:76883787               delins/intronic          NM_000260:c.1798-7_1798-6delCCinsAT          --             ND            ND          --           NA                                  NA         NA   NA   ND                  ND                             --                  --                                      No                                 Male gonadal development? ([@B38]; [@B50])

  8         *MYO7A*      11:76883790               delins/intronic-exonic   NM_000260: c.1798-4_1801delinsGGCTGCT        --             ND            ND          --           NA                                  NA         NA   NA   ND                  ND                             --                  --                                      No                                 Male gonadal development? ([@B38]; [@B50])

  8         *NOTCH1*     9:139405111               snv/missense             NM_017617.5:c.2734C\>T:p.(Arg912Trp)         rs201620358    0.002         ND          31           12                                  6          0    3    Likely benign       VUS                            VUS                 VUS: PP3                                No                                 Related to SHH and FGF10 ([@B32])

  8         *PIK3R3*     1:46521570                snv/missense             NM_003629.3:c.838G\>A:p.(Asp280Asn)          rs186728731    0.0001        ND          25.5         6                                   6          0    2    VUS                 ND                             --                  VUS: PP3                                No                                 Female gonadal development? ([@B5]; [@B38])

  8         *TGFBI*      5:135398870               snv/intronic             NM_000358.2:c.2012-5T\>C                     rs147650812    0.004         0.007       4.531        NA                                  NA         0    4    ND                  ND                             --                  VUS: -                                  No                                 Gonadal development? ([@B38], [@B17], [@B5])

  8         *WNT9A*      1:228109247               snv/missense             NM_003395.3:c.1070G\>A:p.(Arg357His)         rs145836311    0.0010        0.004       34           11                                  5          NA   NA   VUS                 ND                             --                  VUS: -                                  No                                 Female gonadal development? ([@B61]; [@B5])

  8         *WNT9B*      17:44949939               snv/missense             NM_003396.2:c.134C\>T:p.(Pro45Leu)           rs530502749    0.00002       ND          21.1         5                                   4          0    NA   VUS                 ND                             --                  VUS: PM2                                No                                 Mayer--Rokitansky--Küster--Hauser syndrome ([@B81]); bicornuate uterus ([@B81]), organogenesis urogenital system ([@B13]; [@B32])
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All patients were heterozygote for these variants and were checked and confirmed through IGV software (alignment with human genome hg19/grch37; <https://www.broadinstitute.org/igv/>, Broad Institute, Cambridge, MA, USA). (1) Combined exonic predictor CADD: Combined Annotation Dependent Depletion (cutoff score: consensus ≥20; deleterious for DSD ≥18; contained in ANNOVAR). (2) Exonic predictors (funcional impact) (ANNOVAR, 15): SIFT, PolyPhen2 HumDiv, PolyPhen2 HumVar, LRT, MutationTaster, MutationAssessor, FATHEMM, Fathmm-MKL, PROVEAN, VEST3 (Variant Effect Scoring Tool), MetaSVM, MetaLR, MCAP, DANN, fitCons. (3) Exonic predictors (evolutionary conservation) (ANNOVAR, 6): GERP++, phyloP (vertebrate and mammalians), phastCons (vertebrate and mammalians), SiPhy. (4) Splicing predictors (ANNOVAR, 3): splicing predictor from dbscSNV ADA and RF, and SPIDEX splicing predictor (DPSI). (5) Splicing predictors (Alamut software, 5): SSF, MaxEnt, NNSPLICE, GeneSplicer, Ex-Skip. (6) InterVar: Clinical Interpretation of genetic Variants by ACMG/AMP guideline (<http://wintervar.wglab.org/>); ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>); VarSome: The Human Genomics Search Engine (<https://varsome.com/>); ACMG: ACMG classification from VarSome search engine. (7) Human Gene Mutation Database Biobase (HGMD^®^ Professional 2018.2, <http://www.biobase-international.com/product/hgmd>): reported variant: variant class, reference, clinical association Human Gene Mutation Database Biobase. (8) Gene characteristics: evidences for genotype-phenotype correlation. Data obtained from pubmed, HGMD and String. ND, not detected; -, not shown; NA, not analysed; no, not previously related to DSD.

We identified a total of 55 potentially deleterious/candidate heterozygous/hemizygous variants in 41 genes in the eight hemizygous/heterozygous *MAMLD1* patients ([**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}). In the seven 46,XY patients 1--16 variants were found in a total of 1--16 genes, while the 46,XX *MAMLD1* patient revealed 14 additional variants in 13 genes. ([**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}).

Patient 1 harbored nine variants in seven genes: *CYP1A1*, *EVC*, *GRID1*, *NOTCH1*, *RET*, *RIPK4* and *ZBTB16*, all of them associated to gonadal/genital anomalies ([**Table 2**](#T2){ref-type="table"}). Patient 2 carried one variant in *RECQL4*, associated with syndromic hypospadias ([**Table 2**](#T2){ref-type="table"}). Patient 3 presented two variants in two genes: *GLI2* (associated to gonadal/genital anomalies) and *RECQL4* (associated to syndromic hypospadias) ([**Table 2**](#T2){ref-type="table"}). Patient 4 had four variants in four genes: *CDH23*, *COL9A3*, *MAML1* and *NOTCH1*; all, except *MAML1*, have been proposed to be associated with gonadal development ([**Table 2**](#T2){ref-type="table"}). In patient 5, six variants in six genes were found: *BNC2*, *FGF10*, *HSD3B2*, *IRX5*, *MAML2* and *NOTCH2*; all, except *MAML2*, have also been associated with hypospadias or gonadal development ([**Table 2**](#T2){ref-type="table"}). Patient 6 carried 16 variants in 16 genes: *ATF3*, *BNC2*, *CYP1A1*, *EYA1*, *FLNA*, *FRAS1*, *GLI3*, *HOXA13*, *IRX5*, *IRX6*, *MAML1*, *NRP1*, *MAML3, PROP1, PTPN11* and *WDR11* ([**Table 2**](#T2){ref-type="table"}). Thirteen of these genes are associated with risk of hypospadias and/or syndromes that include abnormal gonadal/genital development, whereas *MAML1* is unrelated, *MAML3* has been proposed to be associated with female gonadal development and *PROP1* has only been associated with anterior pituitary insufficiency/hypogonadotropic hypogonadism. In addition, six of these genes have previously been described in patients with aortic diseases and cardiopathies ([**Table 2**](#T2){ref-type="table"}). Patient 7 presented five variants in five genes: *EVC*, *MAML3, NOTCH2*, *PPARGC1B* and *WDR11*; four of them associated with hypospadias or male gonadal development and one, *MAML3*, with female gonadal development ([**Table 2**](#T2){ref-type="table"}). Finally, patient 8 harbored 14 variants in 13 genes: *CUL4B*, *DAPK1*, *EMX2*, *FREM2*, *IGFBP2*, *MAML2*, *MAML3*, *MYO7A*, *NOTCH1*, *PIK3R3*, *TGFBI*, *WNT9A* and *WNT9B*. Among them, only *MAML2* has not been related to gonadal or genitourinary system development ([**Table 2**](#T2){ref-type="table"}).

The following genes showed variants in two patients: *CYP1A1* in patients 1 and 6; *EVC* in patients 1 (2 variants) and 7; *IRX5* in patients 5 and 6; *MAML1* in patients 4 and 6; *MAML2* in patients 5 and 8; *NOTCH2* in patients 5 and 7; *RECQL4* in patients 2 and 3 and *WDR11* in patients 6 and 7 ([**Table 2**](#T2){ref-type="table"}). In addition, 2 genes presented variants in 3 patients: *MAML3* (patients 6, 7 and 8) and *NOTCH1* (patients 1, 4 and 8). Furthermore, *RIPK4* presented 2 variants in patient 1. Finally, *BNC2* variant c.1868C\>A:p.(Pro623His) (MAF = 0.002) was detected in 2 patients (patient 1 and 7) and *MAML3* variant c.881A\>G:p.(Asn294Ser) (MAF = 0.0028) in patients 7 and 8 ([**Table 2**](#T2){ref-type="table"}).

We performed interactome analysis for the identified DSD genes using bioinformatic tools for the analysis of possible gene-protein interactions. The network comprising all genes identified is shown in [**Figure 1**](#f1){ref-type="fig"}. Overall, a connection was found for 27 of the 41 genes. MAMLD1 connects directly to MAML1/2/3. Via NOTCH1/2 8 genes are in connection with MAMLD1, namely WNT9A/9B, GLI2/3, FGF10, RET, PROP1 and NRP1. Some of these genes are also central nodes for further connections; e.g. GLI3 for EVC, FGF10, GLI2, RIPK4 and EYA1; and RET for PIK3R3 with PTPN11, which also is connected with RIPK4. RIPK4 itself is a central node for ZBTB16, CUL4B, GLI3 and PTPN11. NRP1 is connected to FLNA and EYA1 connects with FRAS1 and FREM2. In addition, 2 isolated gene couples have been revealed by our analysis: CYP1A1-HSD3B2 and MYO7A-CDH23. These observations give an idea of the complex interactions among genes related to sex development.

The specific interactome of identified genes in patients 1 and 4 to 8 is shown in [**Figure 2**](#f2){ref-type="fig"}. In patients 1, 4, 5, 7 and 8, MAMLD1 and MAMLD1-related genes (MAML1, MAML2 or MAML3) are directly related to NOTCH1/2 ([**Figures 2A--C, E, F**](#f2){ref-type="fig"}). In patient 1, there are 2 networks: ZBTB16-RIPK4 and MAMLD1-NOTCH1-RET ([**Figure 2A**](#f2){ref-type="fig"}). In patient 6, GLI3, EYA1 and FRAS1 as well as FLNA and NRP1 seem directly related ([**Figure 2D**](#f2){ref-type="fig"}). In patient 8, NOTCH1 plays a central role connecting to WNT9A, WNT9B and MAMLD1 network ([**Figure 2F**](#f2){ref-type="fig"}).

Discussion {#s4}
==========

Sex development is a very complex biological event which requires the concerted collaboration of a large network of genes in a spatial and temporal correct fashion. In the past, much has been learned about human sex development from monogenic DSD, but the broad spectrum of phenotypes in numerous DSD individuals remains a conundrum. Oligogenic disease has been proposed. In fact, multiple genetic hits, which might not be deleterious by themselves, have been found in several individuals with DSD ([@B46]; [@B24]; [@B53]; [@B83]; [@B10]). In a previous study of 46,XY DSD patients carrying *MAMLD1* variants, we showed that none of the variants were functionally pathogenic except for a stop variant ([@B9]). In the present study, we searched for additional genetic hits in DSD patients harboring *MAMLD1* mutations and manifesting with unexplained broad phenotypes. Using HTS and a custom-made algorithm including DSD- and *MAMLD1*-related genes from literature and databases, we identified potentially deleterious genetic variants in additional genes in all *MAMLD1* individuals. Thus, we believe that the broad phenotype of individuals carrying *MAMLD1* variants is due to additional genetic hits.

In our study, we identified 55 additional heterozygous/hemizygous variants in 41 genes in seven 46,XY DSD hemizygous and one 46,XX DSD heterozygous *MAMLD1* patients. Among the 41 genes, 16 have been previously reported in humans with hypospadias (*ATF3, BNC2, CYP1A1, EMX2, EYA1, FLNA, GLI3, GRID1, GLI2,, FGF10, HOXA13, HSD3B2, IRX5, IRX6*, *PPARGC1B* and *WDR11* ([**Table 2**](#T2){ref-type="table"}); 8 have been related to cryptorchidism (*BNC2*, *FLNA, RET, RECQL4, NRP1, PTPN11, RIPK4* and *ZBTB16*), and 5 genes have been found in patients with micropenis (*BNC2, EVC, FGF10, RIPK4 and ZBTB16*). Also, 15 genes have been described in other types of DSD (*CUL4B, EMX2, FRAS1, FREM2, HSD3B2, NOTCH2* and *NRP1*) ([**Table 2**](#T2){ref-type="table"}) and/or were reported in different syndromes (*CYP1A1, EVC, FRAS1, HOXA13, PTPN11, RECQL4, RET, RIPK4* and *ZBTB16*) ([**Table 2**](#T2){ref-type="table"}). In addition, 27 genes had been previously described in the context of sex or gonadal development (*ATF3, BNC2, CDH23, COL9A3, DAPK1, EMX2, EVC, EYA1, FLNA, FRAS1, FREM2, GLI2, GLI3, HOXA13, IGFBP2, IRX5, MAML3, MYO7A, NOTCH1, NOTCH2, NRP1, PIK3R3, RET, RIPK4, TGFBI, WNT9A* and *WNT9B*). Thirteen of these genes have been found involved in female gonadal development and 46,XX DSD (*ATF3, DAPK1, EMX2, FLNA, FRAS1, FREM2, GLI3, IGFBP2, IRX5, MAML3, PIK3R3*, *WNT9A* and *WNT9B*), 8 of which in patient 8 ([**Table 2**](#T2){ref-type="table"}).

According to OMIM, almost all of our patients presented at least one variant in a gene with autosomal dominant inheritance (AD) (*COL9A3, GLI2, FGF10, FLNA, EYA1, GLI3, HOXA13, NOTCH1, NOTCH2, PTPN11, RET, TGFB* and *WDR11*), while other genes (*CDH23, MYO7A* and *PPARGC1B*) may have both AD and autosomal recessive (AR) inheritance. *FLNA* and *CUL4B* are X-linked (XLR), while *CYP1A1, FREM2, EVC, HSD3B2, IRX5, PROP1*, *RAS1, RECQL4*, *RIPK4* and *ZBTB16* are known for AR inheritance. No information on inheritance is currently available for the remaining genes including *ATF3, BNC2, GRID1, DAPK1, IRX6, IGFBP2, MAML1, MAML2, MAML3, NRP1, PIK3R3, WNT9A* and *WNT9B*.

The seven *MAMLD1* patients with 46,XY DSD presented phenotypes from female external genitalia (patient 4) to variable degrees of hypospadias, cryptorchidism and small penis ([**Table 1**](#T1){ref-type="table"}). Interestingly, patient 4 with female external genitalia had normal T secretion. Similarly, patient 5 carrying a heterozygous *HSD3B2* variant, had normal levels of 17OH-pregnenolone, DHEA and DHEA-S (data not shown). Patient 6, who presented with a right aortic arch, was found to carry variants in five genes (*BNC2, FLNA, MAML1, NRP1* and *PTPN11*) that have been previously described in patients with heart and/or vascular anomalies ([@B77]; [@B6]; [@B48]; [@B73]; [@B66]; [@B15]). The 46,XX patient (patient 8), with primary amenorrhea, hypergonadotropic hypogonadism, normal female external genitalia and small uterus harbored gene variants involved in gonadal development and DSD (*CUL4B*, *DAPK1*, *EMX2*, *FREM2*, *IGFBP2*, *MAML3*, *MYO7A*, *NOTCH1*, *PIK3R3*, *TGFBI*, *WNT9A* and *WNT9B*; [**Table 2**](#T2){ref-type="table"}). Five of these genes (*DAPK1, IGFBP2, MAML3, PIK3R3* and *WNT9A*) have so far only been related to female gonadal development ([**Table 2**](#T2){ref-type="table"}).

Overall, the genes detected in our eight studied patients with *MAMLD1* variants have been previously reported in humans with hypospadias, cryptorchidism, micropenis, and other urogenital abnormalities; or they have been found involved in sexual and gonadal development. Also, some of them have been associated with specific syndromes in patients with genitourinary anomalies: CAKUT syndrome, Ellis--van Creveld syndrome, Fraser syndrome 1, Fraser syndrome 2, hand--foot--genital/Guttmacher syndrome, Noonan syndrome, Mayer--Rokitansky--Küster--Hauser syndrome, Popliteal pterygium syndrome and Rothmund--Thomson syndrome (see [**Table 2**](#T2){ref-type="table"}). However, none of the present patients presented a complete phenotype for any of these syndromes, maybe because none of the variants completely impairs gene expression and protein function, as inferred by the *in silico* analyses. Detailed information on these genes from current literature is given in [**Supplementary Materials (S1)**](#SM1){ref-type="supplementary-material"}.

A search for an underlying network comprising variants in the identified genes related to *MAMLD1* revealed a considerable number of genes which showed gene-gene, gene-protein or protein-protein interactions ([**Figures 1**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"}) suggesting that genetic variations in these genes may affect sex development. In addition, *MAML3* was found in a network related to female gonadal development ([@B38]). Accordingly, one variant in *MAML3* was present in our 46,XX patient. The analysis of gene/protein network interactions per patient gives an idea of the complexity of the interactions among genes related to sex development. The more variants detected in DSD-related genes, the better to build an interaction network searching for clues on genetic relationship(s) for sex development. In our DSD individuals carrying *MAMLD1* variants, three genes seemed prominent in the network analysis, *NOTCH1, NOTCH2* and *GLI3*. NOTCH signaling is a highly conserved signaling pathway and comprises 4 transmembrane receptors. It is essential for the regulation of embryonic development of multiple organ systems including gonadal development ([@B84]). NOTCH signaling is implicated in Leydig cell differentiation in an inhibitory regulatory fashion ([@B84]). Autosomal dominant mutations in *NOTCH1* cause the Adams--Oliver syndrome (OMIM 616028), while autosomal dominant mutations in *NOTCH2* are reported in the Alagille syndrome 2 (OMIM 610205) and in the Hajdu--Cheney syndrome (OMIM 102500). By contrast, GLI3 is a zinc-finger transcription factor belonging to the desert hedgehog (DHH) signal transduction pathway. DHH signaling is essential for driving Leydig cell differentiation ([@B84]). Thus, NOTCH and DHH signaling work together to regulate Leydig cell development ([@B84]). Autosomal dominant mutations in *GLI3* are described in the Pallister--Hall syndrome (OMIM 146510) or in the Greig cephalopolysyndactyly syndrome (OMIM 175700).

Taken together, our results expand the landscape of genes possibly involved in DSD by revealing both new and old players. Genetic platforms for DSD diagnostics currently consider about 270 genes that have been identified with monogenetic forms of DSD in (mostly) several independent individuals ([@B19]). Our eight *MAMLD1* individuals share variants in 19 genes comprised in such DSD panels, including *ATF3, BNC2, CUL4B, EVC, FLNA, FRAS1, FREM2, GLI3, HOXA13, HSD3B2, IRX5, NOTCH2, PROP1, PTPN11, RECQL4, RET, RIPK4, WDR11* and *ZBTB16*. By contrast, through our work 22 new genes are now added for considering with differences in sex development: *CDH23, COL9A3, CYP1A1, DAPK1, EMX2, EYA1, FGF10, GLI2, GRID1, IGFBP2, IRX6, MAML1, MAML2, MAML3, MYO7A, NOTCH1, NRP1, PIK3R3, PPARGC1B, TGFBI, WNT9A* and *WNT9B*.

Ideally, genetic variants are tested functionally for proof of their disease-causing effect in model systems. However, when finding multiple variants, which may all contribute only partially, such testing is no longer feasible. Therefore, the likelihood of disease-causing effect of identified variants was assessed in our study by established bioinformatic tools for genetics and by assessing the genotype-phenotype correlation in each patient with current knowledge from literature and databases in the field. In future studies with bigger sample size, next-generation statistical genetic analyses may be employed to identify associations between a group of variants and the complex trait of sex development ([@B82]).

In summary, HTS analysis indicates that the broad DSD phenotypes of *MAMLD1* patients may be due to additional variants in other DSD-related genes. We found up to 55 additional genetic hits that may contribute to the DSD phenotype making an oligogenic causation plausible. Bioinformatic network analysis can help in interpreting complex genetic data and put identified single candidate genes into a greater perspective to understand their possible role in DSD biology.
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